The Trendlines Group
Financial Highlights FY2018

Steve Rhodes
Chairman and CEO

Todd Dollinger
Chairman and CEO

Haim Brosh
Chief Financial Officer

20 February 2019

Agenda

- Corporate highlights
- Financial highlights
- Post FY 2018 developments

Legal disclaimer

Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. ("Company") or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.

Corporate highlights

11 years of portfolio value expansion

Note: For 2018, the portfolio value does not reflect all current portfolio companies due to consolidation of 5 newly-formed companies as subsidiaries controlled by The Trendlines Group.



*Portfolio value includes the fair value of investments in portfolio companies accounted for under the equity method

Key financial developments FY 2018

	31 December 2018	31 December 2017	Change	% Change
Portfolio value	US$ 97.2 million	US$ 96.8 million	US$ 0.4 million	N.M.*
Book value	US$ 86.4 million	US$ 92.9 million	- US$ 6.5 million	-7.0%
Current assets	US$ 11.8 million	US$ 20.4 million	- US$ 8.6 million	-42.2%
	FY 2018	**FY 2017**	**Change**	**% Change**
Total expenses	US$ 8.3 million	US$ 10.1 million	- US$ 1.8 million	-17.8%
Net gain (loss)	(US$ 6.3) million	US$ 3.9 million	- US$ 10.2 million	N.M.

*N.M.= not meaningful

Key corporate developments FY 2018

- B. Braun Medical SAS, announced as acquirer of Stimatix GI Ltd.'s assets
- MOU signed with Nutreco NuFrontiers and Sirius VC (Brazil)
- Trendlines Medical Singapore and A*ccelerate signed MOU
- Established 10 new portfolio companies
- 20 portfolio companies completed investments: Two companies from strategic partners (Johnson & Johnson Innovation and Nutreco)

10 companies to watch*

- ApiFix Ltd.
- Arcuro Medical Ltd.
- BioFishency Ltd.
- Fidmi Medical Ltd.
- Gordian Surgical Ltd.
- **Leviticus Cardio Ltd.**
- OrthoSpin Ltd.
- Saturas Ltd.
- STS Medical Ltd.
- ViAqua Therapeutics Ltd.



*Updated report issued 23 January 2019

A game changer in heart pump technology




Bloomberg

Technology

Heart Pump With Wireless Charging Implanted by Kazakh Doctors

By Nariman Gizitdinov

February 6, 2019, 5:00 AM GMT+2 *Updated on February 6, 2019, 11:08 AM GMT+2*


- First known human experience with this technology [JH].
- Discharged patient with device seen swimming, working out

Doctors in Kazakhstan said Wednesday they had successfully implanted a mechanical heart pump charged wirelessly by an Israeli device, a development aimed at improving life for very ill patients awaiting transplants.

The operation was performed in December at the National Research Center for Cardiac Surgery in Astana, the Israeli technology company Leviticus Cardio said in an emailed statement.

"The patient has been discharged from the hospital and is back leading a

In this article


The Journal of Heart and Lung Transplantation

The Official Publication of the International Society for Heart and Lung Transplantation

Articles & Issues · Press Releases · For Authors · Journal Info · Subscribe · ISHLT · ISHLT Regi

Contact the Journal

All Content · Search · Advanced Search

< Previous Article · Articles in Press · Next Article >

Article in Press

First Human Use of a Wireless Coplanar Energy Transfer Coupled with a Continuous-flow Left Ventricular Assist Device

Yuryi Pya, MD, Jiri Maly, MD, PhD, Mahabbat Bekbossynova, MD, Roman Saloy, MBA, Stephan Schueler, MD, PhD, FRCS, Bart Meyns, MD, PhD, Yigal Kassif, MD, Massimo Massetti, MD, PhD, Michael Zilbershlag, BSc, Ivan Netuka, MD, PhD

Open Access · PlumX Metrics

DOI: https://doi.org/10.1016/j.healun.2019.01.1316

Article Info







Highlights from the “10 Companies to Watch” report


- ApiFix Ltd. and Gordian Surgical Ltd. completed >275 surgeries and >500 surgeries respectively
- Arcuro Medical Ltd. completed 9 successful first-in-human meniscus repair procedures
- STS Medical Ltd. preparing manufacturing capabilities for first approved product
- Leviticus Cardio Ltd. completed successful first in human cases demonstrating wireless power
- OrthoSpin Ltd. completed US$3 million investment round led by Johnson & Johnson Innovation.
- ViAqua Therapeutics Ltd. announced Nutreco NuFrontiers and VisVires New Protein investments

Financial highlights

Consolidated income statement

	Group Full Year Ended 31 December 2018 (Unaudited) US$'000	 31 December 2017 (Audited) US$'000	 Change %
Income:			
Gain (loss) from change in fair value of investments in Portfolio Companies	(6,046)	9,399	N.M
Income from services to Portfolio Companies	5,760	4,904	17.46
Group's share of losses of companies accounted for under the equity method	-	(167)	N.M.
Income from contracted R&D services	476	473	0.63
Financial income	1,248	665	87.51
Other income	360	355	1.41
Total income	1,798	15,629	(88.50)
Expenses			
Operating, general and administrative expenses	6,395	8,579	(25.45)
Marketing expenses	404	354	14.12
R&D expenses, net	1,057	1,111	(4.86)
Financial expenses	428	10	4,180
Total expenses	8,284	10,054	(17.60)
Income (loss) before income taxes	(6,486)	5,575	N.M
Tax benefit (Income tax expenses)	168	(1,643)	(110.22)
Net income (loss)	(6,318)	3,932	N.M

Key value components



* Israeli government loans are non-recourse loans which only come due upon exit events.

** Deferred taxes from unrealized portfolio company valuation profits are offset and paid only upon realization of cash from exits.

Post FY 2018 developments

Post FY 2018 developments

- Two medical portfolio companies established in Singapore as a result of collaboration agreement between Trendlines Medical Singapore Pte. Ltd., National Healthcare Group, and A*ccelerate
- Management changes for 2019 announced
- Publicized successful first in human case for portfolio company Leviticus Cardio Ltd.'s paradigm-shifting wireless heart pump system


Bloomberg

Technology

Heart Pump With Wireless Charging Implanted by Kazakh Doctors

By Nariman Gizdinov

February 6, 2019, 5:00 AM GMT+2 *Updated on February 6, 2019, 11:08 AM GMT+2*

Looking ahead: Trendlines Agrifood Fund

US$40 million agrifood tech-focused venture fund

- Will employ a blended **early/late-stage investment strategy** to
  - achieve early exits
  - attain IRR of at least 20%



Trendlines Group VP **Nitza Kardish, PhD,** will relocate to Singapore to oversee and coordinate the Fund's activities.

Singapore Government Support

- **Prominent Singapore investment fund** committed to invest 25% of fund, up to US$10 million
- **Enterprise Singapore**
  - Early-stage companies can access proof-of-concept and proof-of-value funding, up to a total of SGD 750,000 per company at favorable terms
  - Application pending for grant funding for incubator
- **SEEDS Capital** agreed to co-invest with Fund
  - Initial commitment: SGD 5 million
  - 70% of SEEDS' profits paid to the Fund, increasing Fund yield

trendlines
medical • agtech • labs

Creating and developing companies **to improve the human condition**

SGX: 42T
OTCQX: TRNLY

+972.72.260.7000
www.trendlines.com

Steve Rhodes, Chairman & CEO
steve@trendlines.com

Todd Dollinger, Chairman & CEO
todd@trendlines.com

Haim Brosh, Chief Financial Officer
haim@trendlines.com

20 February 2019